EP1003530A4 - Traitement oculaire a l'aide de compositions d'hormones thyroidiennes synthetiques - Google Patents

Traitement oculaire a l'aide de compositions d'hormones thyroidiennes synthetiques

Info

Publication number
EP1003530A4
EP1003530A4 EP97938483A EP97938483A EP1003530A4 EP 1003530 A4 EP1003530 A4 EP 1003530A4 EP 97938483 A EP97938483 A EP 97938483A EP 97938483 A EP97938483 A EP 97938483A EP 1003530 A4 EP1003530 A4 EP 1003530A4
Authority
EP
European Patent Office
Prior art keywords
thyroid hormone
eye treatment
synthetic thyroid
hormone compositions
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97938483A
Other languages
German (de)
English (en)
Other versions
EP1003530A1 (fr
Inventor
Daniel M Schwartz
John D Baxter
Michele D Jumper
Thomas S Scanlan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of EP1003530A1 publication Critical patent/EP1003530A1/fr
Publication of EP1003530A4 publication Critical patent/EP1003530A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
EP97938483A 1996-08-20 1997-08-20 Traitement oculaire a l'aide de compositions d'hormones thyroidiennes synthetiques Withdrawn EP1003530A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2369796P 1996-08-20 1996-08-20
US23697P 1996-08-20
PCT/US1997/014691 WO1998007435A1 (fr) 1996-08-20 1997-08-20 Traitement oculaire a l'aide de compositions d'hormones thyroidiennes synthetiques

Publications (2)

Publication Number Publication Date
EP1003530A1 EP1003530A1 (fr) 2000-05-31
EP1003530A4 true EP1003530A4 (fr) 2001-10-04

Family

ID=21816699

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97938483A Withdrawn EP1003530A4 (fr) 1996-08-20 1997-08-20 Traitement oculaire a l'aide de compositions d'hormones thyroidiennes synthetiques

Country Status (6)

Country Link
US (3) US6054485A (fr)
EP (1) EP1003530A4 (fr)
JP (2) JP3345428B2 (fr)
KR (1) KR100405285B1 (fr)
CA (1) CA2260992C (fr)
WO (1) WO1998007435A1 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6266622B1 (en) * 1995-12-13 2001-07-24 Regents Of The University Of California Nuclear receptor ligands and ligand binding domains
DE69636677D1 (de) 1995-12-13 2006-12-14 Univ California Kristalle der mit einem Ligand komplexierten Ligandenbindedomäne des Schilddrüsenhormonrezeptors
US20020143284A1 (en) * 2001-04-03 2002-10-03 Hosheng Tu Drug-releasing trabecular implant for glaucoma treatment
US7163918B2 (en) * 2000-08-22 2007-01-16 New River Pharmaceuticals Inc. Iodothyronine compositions
FR2816633B1 (fr) * 2000-11-10 2003-02-07 Lipha Methode de criblage d'agents susceptibles de traiter l'obesite
US20030229062A1 (en) * 2001-12-07 2003-12-11 The Regents Of The University Of California Treatments for age-related macular degeneration (AMD)
US7470659B2 (en) * 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
WO2003049685A2 (fr) * 2001-12-07 2003-06-19 The Regents Of The University Of California Traitement de la degenerescence maculaire liee au vieillissement
US7018646B2 (en) * 2002-05-30 2006-03-28 Van Dalen Johan T W Apparatus and method for delivering controlled quantities of one or more agents to the eye
US20050048099A1 (en) * 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US20040216749A1 (en) * 2003-01-23 2004-11-04 Hosheng Tu Vasomodulation during glaucoma surgery
US6969514B2 (en) * 2003-02-05 2005-11-29 Soll David B Method for treating elevated intraocular pressure, including glaucoma
EP1689383B1 (fr) 2003-11-19 2012-10-31 Metabasis Therapeutics, Inc. Nouvelles substances thyromimetiques contenant du phosphore
EP1765454B1 (fr) 2004-07-02 2016-04-13 Mati Therapeutics Inc. DISPOSITIF DE MISE EN PLACE D'UN MOYEN DE TRAITEMENT POUR l'OEIL
CA2606499C (fr) 2005-05-26 2017-06-13 Metabasis Therapeutics, Inc. Composes thyromimetiques utilises pour traiter les maladies hepatiques graisseuses
US20090028925A1 (en) * 2005-05-26 2009-01-29 Erion Mark D Novel Phosphinic Acid-Containing Thyromimetics
CN101291640A (zh) * 2005-06-24 2008-10-22 托马斯·拉文 甲状腺素化合物用于人体烧伤和脂肪沉积的治疗
US20080000473A1 (en) * 2005-12-29 2008-01-03 Hugo Stephenson pH-Based Methods and Devices for Preventing Hemagglutinin Cell Membrane Fusion
EP2004172B1 (fr) 2006-03-31 2019-03-13 Mati Therapeutics Inc. Structures d'administration de médicaments et compositions utilisées dans le système nasolacrymal
FR2924722B1 (fr) * 2007-12-10 2013-10-25 Oreal Procede de selection d'agents pour modifier la forme du cheveu et utilisation cosmetique des actifs.
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
WO2013011511A1 (fr) 2011-07-18 2013-01-24 Mor Research Applications Ltd. Dispositif pour l'ajustement de la tension intraoculaire
TWI775096B (zh) 2012-05-15 2022-08-21 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
WO2014178892A1 (fr) 2013-05-03 2014-11-06 Scanlan Thomas S Utilisation du sobetirome dans le traitement de l'adrénoleucodystrophie liée au chromosome x
US10258613B2 (en) 2014-02-05 2019-04-16 The Board Of Regents Of The University Of Oklahoma Compositions for treating retinal degeneration and methods of production and use thereof
EP3800191B1 (fr) 2014-03-17 2025-08-20 Adverum Biotechnologies, Inc. Compositions et procédés pour améliorer l'expression des gènes dans les cônes rétiniens
JP7095994B2 (ja) 2015-03-02 2022-07-05 アドヴェラム バイオテクノロジーズ， インコーポレイテッド ポリヌクレオチドを網膜錐体に硝子体内送達するための組成物及び方法
AU2016266584B2 (en) 2015-03-04 2020-09-10 President And Fellows Of Harvard College Fluidic device for quantifying the dynamic permeability and hydraulic conductivity of living tissue layers
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
CA3044059A1 (fr) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Methodes de traitement de glycogenose
EA201992703A1 (ru) 2017-06-05 2020-04-15 Вайкинг Терапьютикс, Инк. Композиции для лечения фиброза
CA3094167A1 (fr) 2018-03-22 2019-09-26 Viking Therapeutics, Inc. Formes cristallines et procedes de production de formes cristallines d'un compose
WO2020117962A1 (fr) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions pour le traitement de la fibrose et de l'inflammation
WO2020123861A1 (fr) 2018-12-12 2020-06-18 Autobahn Therapeutics, Inc. Nouveaux thyromimétiques
CN113784950A (zh) 2019-03-01 2021-12-10 速通医疗公司 新型拟甲状腺素药
AU2020391467A1 (en) 2019-11-29 2022-06-23 Autobahn Therapeutics, Inc. Novel thyromimetics
JP2023515827A (ja) * 2020-02-28 2023-04-14 ノースウェスタン ユニバーシティ 房水流出を高め、眼圧を減少させる方法
EP4167986A4 (fr) 2020-06-17 2024-11-20 Autobahn Therapeutics, Inc. Thyromimétiques
EP4168384A4 (fr) 2020-06-17 2024-07-10 Autobahn Therapeutics, Inc. Thyromimétiques

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017178A1 (fr) * 1993-12-22 1995-06-29 The Regents Of The University Of California Inhibiteurs non steroides pour le traitement de l'elevation de la pression intraoculaire
WO1997021993A2 (fr) * 1995-12-13 1997-06-19 The Regents Of The University Of California Ligands de recepteurs nucleaires et domaines de liaison de ligands

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2798053A (en) * 1952-09-03 1957-07-02 Goodrich Co B F Carboxylic polymers
US4038264A (en) * 1974-01-07 1977-07-26 National Patent Development Corporation Hema copolymers having high oxygen permeability
US4192827A (en) * 1974-06-27 1980-03-11 Ciba-Geigy Corporation Water-insoluble hydrophilic copolymers
US4136250A (en) * 1977-07-20 1979-01-23 Ciba-Geigy Corporation Polysiloxane hydrogels
US4548990A (en) * 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
CN1011118B (zh) * 1986-06-13 1991-01-09 天津医学院附属医院 治疗白内障的眼药水的制药方法
FR2601247A1 (fr) * 1986-07-09 1988-01-15 Merk Sharp Dohme Chibret Labor Combinaison d'agents beta-bloquants et de pilocarpine.
US5360399A (en) * 1992-01-10 1994-11-01 Robert Stegmann Method and apparatus for maintaining the normal intraocular pressure
US6221911B1 (en) 1995-06-07 2001-04-24 Karo Bio Ab Uses for thyroid hormone compounds or thyroid hormone-like compounds
JPH11508241A (ja) * 1995-06-07 1999-07-21 カロ バイオ エービー 甲状腺ホルモンまたは甲状腺ホルモン様化合物に関する新規な使用
US6380255B1 (en) 1995-06-07 2002-04-30 Karo Bio Ab Treatment for dermal skin atrophy using thyroid hormone compounds or thyroid hormone-like compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017178A1 (fr) * 1993-12-22 1995-06-29 The Regents Of The University Of California Inhibiteurs non steroides pour le traitement de l'elevation de la pression intraoculaire
WO1997021993A2 (fr) * 1995-12-13 1997-06-19 The Regents Of The University Of California Ligands de recepteurs nucleaires et domaines de liaison de ligands

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HALLMAN, VIVIENNE L.: "Effect of thyroid hormones on intraocular pressure", EXP. EYE RES. (1967), 6(3), 219-26, XP001002983 *
See also references of WO9807435A1 *
SMITH K.D. ET AL: "An association between hypothyroidism and primary open-angle glaucoma.", OPHTHALMOLOGY, (1993) 100/10 (1580-1584)., XP001016291 *
YONEYAMA, JOJI: "Effects of antiglaucoma agents on glycosaminoglycans in organ-cultured rabbit trabecular meshwork", OPHTHALMOLOGICA (1994), 208(5), 278-83, XP002174077 *

Also Published As

Publication number Publication date
WO1998007435A1 (fr) 1998-02-26
US6555582B1 (en) 2003-04-29
US7122579B2 (en) 2006-10-17
CA2260992C (fr) 2004-03-09
US6054485A (en) 2000-04-25
AU717608B2 (en) 2000-03-30
EP1003530A1 (fr) 2000-05-31
KR20000068213A (ko) 2000-11-25
JP3345428B2 (ja) 2002-11-18
CA2260992A1 (fr) 1998-02-26
JP2002348249A (ja) 2002-12-04
AU4079397A (en) 1998-03-06
US20030175849A1 (en) 2003-09-18
JP2001500964A (ja) 2001-01-23
KR100405285B1 (ko) 2003-11-12

Similar Documents

Publication Publication Date Title
ATE207732T1 (de) Zusammensetzung zur remineralisierung
DE69219418D1 (de) Zusammensetzung zur Revitalisierung von Nerbgewebe
BR9504194A (pt) Composiçao de poliuretano
FI970563A0 (fi) Parannettu puhdistuskoostumus
FI964338A0 (fi) Sellulaasia sisältäviä kankaanhoitoainekoostumuksia
DE69718508D1 (de) Antitraspirant zusammensetzung
DE69733506D1 (de) Schmierende Zusammensetzung
DE69830659D1 (de) Leitgährige zusammensetzung,verbundstoff dafür und verfahren zur herstellung dieser zusammensetzung und dieses verbundstoffes
DE69501298D1 (de) Polypropylenzusammensetzung
ID18359A (id) Komposisi mikrokapsul
DE69721436D1 (de) Antibakterielle wasserabsorbierende Zusammensetzung und Verfahren zur Herstellung davon
DE69937171D1 (de) Verfahren zur Herstellung von arylierten Poly-alpha-Olefinen
ID19589A (id) Komposisi
DE19781549T1 (de) Desinfektionszusammensetzung "Weltolen"
DE69706351D1 (de) Reinigungszusammensetzung
BR9506925A (pt) Composição de limpeza
ID22707A (id) Komposisi pembersih
DE59712835D1 (de) Stabilisierte monomerenzusammensetzung
DE69709695T8 (de) Verfahren zur seitenzusammensetzung
DE69729604D1 (de) Zusammensetzung zur Geruchsverstärkung
DE69423487D1 (de) Einrichtung zur aquakultur
BR9707835A (pt) Composiç
DE69708032D1 (de) Verfahren zur Herstellung von Trimethylcatecholdiestern
DE59713017D1 (de) Verfahren zur Herstellung von Alkylhalogensilanen
DE69532410D1 (de) Härtbare zusammensetzung

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990315

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 33/36 A, 7A 61K 49/00 B, 7A 61K 31/195 B

A4 Supplementary search report drawn up and despatched

Effective date: 20010820

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20020909

17Q First examination report despatched

Effective date: 20020909

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080206